Chen Meng-Meng, Zhang Bing-Qiang, Luan Yan-Song, Sun Guo-Long, Zhang Yun-Yuan, Zhou Xiao-Yan, Zhang Xi-Feng, Gao Feng-Chun, Yu Jun-Mei
Qingdao Restore Medical Laboratory Co., Ltd., Qingdao, Shandong, China.
Key Laboratory of Cancer and Immune Cells of Qingdao, Qingdao, China.
Front Immunol. 2025 Jul 24;16:1634297. doi: 10.3389/fimmu.2025.1634297. eCollection 2025.
This study aims to systematically evaluate the application value of gene methylation detection in cervical lesion screening and its potential advantages in the triage of non-16/18 high-risk human papillomavirus (HR-HPV) positive patients.
This study enrolled 1,619 HPV-positive female patients who visited the Affiliated Hospital of Qingdao University from December 2023 to March 2025, with 989 patients ultimately meeting the inclusion criteria. All subjects underwent HPV-DNA testing, cytological examination, colposcopy, and gene methylation detection, with results analyzed in conjunction with histopathological evaluations. HPV-DNA detection was performed using fluorescence quantitative PCR methodology capable of identifying 17 high-risk HPV genotypes. Cytological examination results were classified according to the International Society of Cytology standards. gene methylation detection employed fluorescence quantitative PCR technology with ACTB as the internal reference gene, determining methylation levels through calculation of ΔCT values. Statistical analyses included ROC curve assessment of diagnostic performance, with intergroup comparisons conducted using one-way analysis of variance and Pearson's chi-squared test.
The results demonstrated that PAX1 gene methylation detection showed significantly better diagnostic performance compared to cytological examination for the detection of CIN2+ and CIN3+ lesions. The AUC values for gene methylation detection in diagnosing CIN2+and CIN3+ were 0.934 (95% confidence interval [CI]: 0.916-0.948) with sensitivity of 93.49% and specificity of 93.24%and0.875 (95% confidence interval [CI]: 0.853-0.895)with sensitivity of 95.31% and specificity of 79.77%. Among non-16/18 HR-HPV(in women positive for high-risk HPV types other than 16/18) positive patients, gene methylation detection demonstrated higher sensitivity and specificity than cytological examination, enabling more accurate identification of patients requiring further intervention and reducing unnecessary colposcopy referrals. Furthermore, in HR-HPV positive patients with cytology results ≤ASCUS, gene methylation detection significantly decreased colposcopy referral rates (22.29%), thus alleviating patients' medical burden.
gene methylation detection exhibits strong diagnostic efficiency for cervical lesions and holds significant value in triage diagnosis of non-16/18 HR-HPV positive.
本研究旨在系统评价基因甲基化检测在宫颈病变筛查中的应用价值及其在非16/18型高危人乳头瘤病毒(HR-HPV)阳性患者分流中的潜在优势。
本研究纳入了2023年12月至2025年3月期间就诊于青岛大学附属医院的1619例HPV阳性女性患者,最终989例患者符合纳入标准。所有受试者均接受HPV-DNA检测、细胞学检查、阴道镜检查和基因甲基化检测,并结合组织病理学评估分析结果。HPV-DNA检测采用能够鉴定17种高危HPV基因型的荧光定量PCR方法。细胞学检查结果根据国际细胞学学会标准进行分类。基因甲基化检测采用以ACTB为内参基因的荧光定量PCR技术,通过计算ΔCT值确定甲基化水平。统计分析包括诊断性能的ROC曲线评估,组间比较采用单因素方差分析和Pearson卡方检验。
结果表明,PAX1基因甲基化检测在检测CIN2+和CIN3+病变方面的诊断性能明显优于细胞学检查。基因甲基化检测诊断CIN2+和CIN3+的AUC值分别为0.934(95%置信区间[CI]:0.916-0.948),灵敏度为93.49%,特异度为93.24%;以及0.875(95%置信区间[CI]:0.853-0.895),灵敏度为95.31%,特异度为79.77%。在非16/18 HR-HPV(16/18型以外的高危HPV类型阳性的女性)阳性患者中,基因甲基化检测显示出比细胞学检查更高的灵敏度和特异度,能够更准确地识别需要进一步干预的患者,减少不必要的阴道镜转诊。此外,在细胞学结果≤ASCUS的HR-HPV阳性患者中,基因甲基化检测显著降低了阴道镜转诊率(22.29%),从而减轻了患者的医疗负担。
基因甲基化检测对宫颈病变具有较强的诊断效能,在非16/18 HR-HPV阳性的分流诊断中具有重要价值。